RxDoctor Payments Data

Lee Allison, MD

Family Medicine · Mt Pleasant, SCNPI 1417037078

Payments from drug & device makers

$255in general payments, 2019–2025

Across 8 payments — averaging $31.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$130
  • Medtronic$66
  • AbbVie$18
  • Novo Nordisk$15
  • Takeda Pharmaceuticals U.S.A., Inc.$14
  • Teva Pharmaceuticals USA, Inc.$11
  • plus $1 from 1 others

What the payments were for

  • Food & beverage$254100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$255 in reported general payments places this provider in the 40th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$115,489
Medicare patients
238
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide124$138,980
OzempicSemaglutide81$103,549
EliquisApixaban39$39,799
LinzessLinaclotide35$32,453
Tresiba Flextouch U-200Insulin Degludec16$32,226
JardianceEmpagliflozin21$31,126
RybelsusSemaglutide15$25,913
JanuviaSitagliptin Phosphate27$24,517
Tresiba Flextouch U-100Insulin Degludec25$20,792
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$19,272
Ajovy AutoinjectorFremanezumab-Vfrm11$15,377
Nurtec OdtRimegepant Sulfate11$9,369
Rosuvastatin Calcium244$2,768
SynthroidLevothyroxine Sodium47$2,640
Ezetimibe31$2,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$15$129,46296 claims
AbbVieLinzess, Synthroid$18$35,09382 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →